Diabetes & vascular disease research最新文献

{"title":"Relationship between non-O blood groups and microvascular risk in type 2 diabetes.","authors":"Fabian O Lurquin, Elise L Petit, Philippe Oriot, Sylvie A Ahn, Michel P Hermans","doi":"10.1177/14791641261474101","DOIUrl":"10.1177/14791641261474101","url":null,"abstract":"<p><p>IntroductionABO groups impact macroangiopathy risk in T2D. It is unknown whether such modulation extends to microvascular complications.MethodSingle-centre cross-sectional study including 1,006 T2D patients.ResultsPrevalence of overall microangiopathy was 51%. No significant differences (ANOVA) were observed between ABO groups in terms of age, sex, diabetes duration, BMI, hypertension, chronic kidney disease or diabetic foot. Insulin sensitivity and the hyperbolic HOMA product [BxS] were lower among non-O groups (-20% and -14%, respectively; p 0.001 and 0.013), while HbA1c and lifetime hyperglycaemia exposure were higher (+5% and +25%, respectively; p 0.006 and 0.002). Overall microangiopathy was more prevalent among non-O patients (+23%; p 0.001), as was neuropathy (+44%; p 0.005). Differences across ABO groups were significant for overall microangiopathy (p 0.009) and neuropathy (p 0.027) (ANOVA). In multivariate analysis, group A (vs O) was associated with overall microangiopathy (OR=1.62; 95%CI: 1.18-2.22; p 0.003) after adjustment for diabetes duration, HbA1c, smoking, remnant-C and hypertension.ConclusionT2D patients of blood group A have increased frequency of overall microangiopathy, regardless of other risk factors. Group O subjects exhibit better glucose homeostasis, with better insulin sensitivity and β-cell function. The ABO system therefore impacts both glucose homeostasis and microvascular susceptibility in T2D.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 4","pages":"14791641261474101"},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148633226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemoglobin A1c association patterns with cardiovascular outcomes among patients with diabetes mellitus following percutaneous coronary intervention: A systematic review.","authors":"Ayesha Tariq, Zohra Bhatti, Muhammad Nabeel Akbar Chaudary, Madeeha Laghari, Amer Hayat Khan, Nor Ilyani Binti Mohamed Nazar, Bandeh Ali Talpur","doi":"10.1177/14791641251400354","DOIUrl":"10.1177/14791641251400354","url":null,"abstract":"<p><p>BackgroundCardiovascular complications are the leading cause of mortality in patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI). This systematic review aims to evaluate the association between HbA1c levels and major adverse cardiovascular events (MACE) in patients with DM post-PCI.MethodsA comprehensive literature search was conducted following PRISMA guidelines. Eligible studies included randomized controlled trials, cohort studies, and observational analyses assessing the impact of strict, moderate, and poor glycaemic control on cardiovascular outcomes. Data extraction focused on HbA1c levels, MACE incidence, cardiovascular mortality, and cardiovascular complications.ResultsNine studies with 24,978 participants were included. U-shaped and J-shaped relationships were found between HbA1c levels and cardiovascular outcomes. Moderate glycaemic control (HbA1c 6.5%-7.5%) was associated with the lowest risk of MACE and mortality. In contrast, strict glycaemic control (HbA1c <6.5%) and poor control (HbA1c >7.5%) were linked to increased cardiovascular risk. Patients with HbA1c below 5.5% exhibited a significantly higher risk of cardiovascular mortality, while HbA1c above 8% was also associated with poor outcomes.ConclusionMaintaining HbA1c levels in the moderate range (6.5%-7.5%) appears to provide optimal cardiovascular protection for patients with DM post-PCI. Strict or poor glycaemic control increases the risk of adverse outcomes.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 3","pages":"14791641251400354"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13264666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148254926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes mellitus and abdominal aortic aneurysm growth: Clinical evidence and mechanistic insights.","authors":"Margaret Dimova, Bistra Boneva, Boris Ilchev","doi":"10.1177/14791641261460038","DOIUrl":"10.1177/14791641261460038","url":null,"abstract":"<p><p>BackgroundDiabetes mellitus (DM) has paradoxically been associated with slower abdominal aortic aneurysm (AAA) growth, despite its adverse vascular profile.MethodsWe present a focused synthesis of contemporary longitudinal cohort studies reporting AAA growth rates according to diabetes status and metformin exposure.ResultsAcross six independent cohorts, patients with diabetes consistently exhibited slower aneurysm expansion compared with patients without diabetes, with reported differences of approximately 0.5-1.5 mm/year. Three cohorts further demonstrated that metformin use was independently associated with additional attenuation of AAA growth, with an adjusted reduction of approximately 0.3-0.4 mm/year.ConclusionAvailable clinical evidence consistently supports an inverse association between diabetes and AAA growth, with metformin emerging as a potential disease-modifying factor. These findings highlight metabolic modulation as a promising avenue for individualized surveillance strategies and future therapeutic investigation in AAA.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 3","pages":"14791641261460038"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.","authors":"Abdul Qadeer, Marwah Bintay Khalid, Ridwan Syed, Samiksha Jain, Faiza Zakaria, Muhammad Huzaifa Ahmed Khan, Najam Gohar, Ashraf Shoukat, Ibrahim Mortada, Izhan Hamza, Afaq Motiwala, Muhammad Waheed Raja, Thomas Blackwell, Hani Jneid","doi":"10.1177/14791641261465360","DOIUrl":"10.1177/14791641261465360","url":null,"abstract":"<p><p>BackgroundWith the increasing use of GLP-1 receptor agonists and dual GIP/GLP-1 agonists for managing obesity and type 2 diabetes, understanding their real-world effectiveness and safety is essential. This TriNetX analysis directly compares clinical outcomes among patients treated with tirzepatide vs semaglutide.MethodWe utilized data from the TriNetX Research Network, identifying patients aged > 40 years or with obesity (\"BMI ≥ 30 kg/m2\") and type 2 diabetes (HbA1c ≥ 6.5% or fasting glucose.≥ 125 mg/dL). Qualifying events were restricted to May 1, 2022, through November 21, 2024. We established two cohorts: one initiating tirzepatide and another semaglutide, ensuring each patient had at least three prescriptions and no prior exposure to the comparator drug or other GLP-1 receptor agonists. The index date was defined as the first co-occurrence of the obesity/diabetes criteria and the respective drug prescription. To ensure comparability, we performed 1:1 propensity matching, resulting in 47,804 patients in each cohort. Outcomes, including all-cause mortality, MACE, heart failure exacerbation, ischemic stroke/TIA, hospitalization/ED use, dementia, UTI, adverse Gastrointestinal (GI) effects, and changes in HbA1c, were assessed within a 1-year window after the index date.ResultsOur matched cohort had a mean age of 75 years, with 45% male patients and 74% identified as white. Patients treated with tirzepatide experienced a significantly lower incidence of MACE at \"(\"3.7% vs 4.1% (RR 0.918, 95% CI 0.862-0.978). All-cause mortality was also lower with tirzepatide (0.2% vs. 0.4%; Risk Ratio 0.436, 95% CI 0.338-0.562). The tirzapetide group achieved better glycemic control with a lower mean HbA1c (6.565% vs. 6.848%; p < 0.001) during the follow-up. There was no significant difference in heart failure exacerbation or UTI incidence. GI side effects were slightly less frequent in the tirzepatide cohort (9.8% vs. 10.2%; Risk Ratio 0.959, 95% CI 0.924-0.997), while hospitalization or emergency visits were comparable between the two groups.ConclusionIn this propensity matched cohort of patients with obesity and type 2 diabetes, tirzepatide demonstrated improved cardiometabolic outcomes compared to semaglutide, including lower all-cause mortality and lower HbA1c. These findings support the cardiovascular safety and efficacy of tirzapetide and highlight the need for further studies to evaluate its effectiveness in broader clinical populations.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 3","pages":"14791641261465360"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148355127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in cardiovascular disease risk in type 1 diabetes: The vascular bed paradox in women.","authors":"Abigayle B Simon, Dhruti Trivedi, Marsha Blackburn, Jeffrey Thomas, Matthew S Nicholson, Lawrence C Layman, Ryan A Harris","doi":"10.1177/14791641261454510","DOIUrl":"10.1177/14791641261454510","url":null,"abstract":"<p><p>BackgroundCardiovascular disease (CVD) is the leading cause of death in individuals with type 1 diabetes (T1D). Epidemiological studies indicate that women with T1D are at greater risk of CVD compared to men with T1D. The present study sought to investigate differences in vascular health between men and women with T1D.Methods53 women with T1D and 25 men with T1D participated in this study. The flow-mediated dilation (FMD) test assessed endothelial-dependent conduit vessel function and nitroglycerin (NTG) was used to assess endothelial-independent vasodilation. In addition, cutaneous post-occlusive reactive hyperemia (PORH), local thermal heating (LTH), and iontophoresis of acetylcholine (ACH) were conducted to assess microvascular function, and pulse wave velocity (PWV) and pulse wave analysis (AIx75) were used as indices of arterial and aortic stiffness, respectively. Near-infrared spectroscopy was utilized to assess skeletal muscle oxidative capacity (SMOC).ResultsHemoglobin A_1c (<i>p</i>=0.904) was similar between men and women with T1D. Women with T1D exhibited higher FMD (<i>p</i>=0.010) and AIx75 (<i>p</i><0.001) compared with men with T1D. There were no differences in PORH, LTH, ACH, PWV, or SMOC between groups (all <i>p</i>>0.05).DiscussionFindings from the present investigation demonstrate that women with T1D exhibit greater conduit vessel endothelial function yet increased aortic stiffness compared to men with T1D. This paradox of enhanced endothelial function and arterial stiffness highlights the complex relationship between vascular structure and function in T1D and the need to assess multiple indices of vascular health when evaluating cardiovascular disease risk in men and women with T1D.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 3","pages":"14791641261454510"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148102146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between SGLT2 inhibitors and recurrence of cerebrovascular events in patients with type 2 diabetes: A population-based cohort study.","authors":"Mee Hyeon Kim, Jin Yeon Gil, Kyung Hyun Min, Jun Hyeob Kim, Jun Hyuk Park, Sunny Park, Ji Min Han, Kyung Eun Lee","doi":"10.1177/14791641261431777","DOIUrl":"10.1177/14791641261431777","url":null,"abstract":"<p><p>ObjectiveSodium-glucose cotransporter 2 (SGLT2) inhibitors have been studied for their effects on cardiovascular disease, cognitive impairment, dementia, Parkinson's disease, and cerebrovascular disease, with evidence suggesting a reduced risk of mortality. This study aimed to examine the association between SGLT2 inhibitors and cerebrovascular event recurrence.MethodsThe cohort was extracted from the Korean National Health Insurance Service Database, including individuals aged 19 or older diagnosed with type 2 diabetes. SGLT2 inhibitor users were compared with metformin users using 1:4 propensity score matching.ResultsAmong study subjects, 1563 (7.8%) experienced recurrent cerebrovascular events. SGLT2 inhibitor users showed lower recurrence of cerebral infarction compared to metformin users (adjusted hazard ratio=0.84, p=0.010). Among the types of cerebrovascular diseases, ischemic stroke was associated with a significantly lower risk of recurrence in SGLT2 inhibitor users than metformin users (aHR=0.70, p=0.020). In the SGLT2 inhibitor group, concurrent use of DPP4 inhibitors was associated with a reduced risk of cerebrovascular event recurrence (aHR=0.69, p=0.011).ConclusionSGLT2 inhibitor use was associated with a significantly lower risk of recurrent cerebral infarction compared to metformin, suggesting a potential role in the secondary prevention of cerebrovascular events in patients with type 2 diabetes.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 2","pages":"14791641261431777"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of colchicine for secondary prevention of cardiovascular diseases in individuals with diabetes: A meta-analysis of randomized trials.","authors":"Niludi Ranwanee Yasaratna, Danushi Wijekoon, Jean-Claude Tardif, Christopher Reid","doi":"10.1177/14791641261418934","DOIUrl":"10.1177/14791641261418934","url":null,"abstract":"<p><p>AimsColchicine is effective for secondary prevention of major adverse cardiovascular events (MACE), yet its benefit in individuals with diabetes remains uncertain despite their elevated cardiovascular risk. This systematic review and meta-analysis assessed the impact of colchicine on cardiovascular outcomes in individuals with diabetes.MethodsDatabases were searched from inception to November 2024 for randomized controlled trials assessing colchicine for reducing MACE. A meta-analysis was performed using RevMan 5.4 with a fixed-effects inverse-variance model to generate pooled risk ratios (RR, HR). PROSPERO registration: CRD42024575366.ResultsFive RCTs were included, comprising 2977 participants with diabetes (1492 (50%) colchicine; 1485 (50%) placebo/usual care). Most were males over 60 years. Colchicine significantly reduced MACE, HR 0.79 (95% CI 0.67-0.94, p = 0.006). Subgroup analysis of diabetic versus non-diabetic participants yielded a similar effect, HR 0.75 (95% CI 0.67-0.83, p < 0.001). Colchicine did not increase adverse events: composite events RR 0.81 (95% CI 0.68-0.96; <i>p</i> = 0.02), gastrointestinal events RR 1.09 (95% CI 0.98-1.20, p = 0.12), or musculoskeletal events RR 0.77 (95% CI 0.43-1.38, p = 0.39). Benefits were observed with 0.5 mg daily over a median 28.6 months.ConclusionColchicine is associated with a reduction in major cardiovascular events in individuals with diabetes, with consistent long-term benefit at low doses without an increase in adverse effects.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 2","pages":"14791641261418934"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147523229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum LINC00861: A novel biomarker for diabetic nephropathy diagnosis and a promoter of renal injury via miR-378a-3p.","authors":"Haihui Li, Mengmeng Pu, Hong Xia, Dongcai Feng, Qiong Xiao","doi":"10.1177/14791641261431771","DOIUrl":"10.1177/14791641261431771","url":null,"abstract":"<p><p>ObjectiveThis study investigated the expression and diagnostic significance of LINC00861 in DN and explored its functional mechanisms in high glucose-induced cell damage.MethodsWe enrolled 285 participants: 92 healthy controls, 98 uncomplicated T2DM patients, and 95 DN patients. Serum LINC00861 and miR-378a-3p levels were measured via qRT-PCR. Correlations with clinical parameters were assessed using Pearson analysis. Logistic regression identified risk factors for DN progression, and ROC curves evaluated diagnostic accuracy. In vitro, LINC00861 was knocked down to assess its effects on proliferation, inflammation, and oxidative stress under high glucose. Targeting of miR-378a-3p was confirmed by dual-luciferase and RIP assays.ResultsThe LINC00861 expression was significantly elevated in DN patients compared to T2DM and healthy controls, and correlated positively with FBG, HbA1c, and albuminuria, but negatively with eGFR. Multivariate analysis identified LINC00861 as an independent risk factor for DN. The AUC for distinguishing T2DM from DN was 0.918. miR-378a-3p expression was significantly lower in DN patients than in those with T2DM or healthy controls. LINC00861 silencing may alleviate HG induced aberrant proliferation, inflammatory responses, and oxidative stress, possibly via the regulation of miR-378a-3p.ConclusionThe LINC00861 is upregulated in DN and may facilitate renal injury by sponging miR-378a-3p, indicating its potential as a diagnostic biomarker and therapeutic target.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 2","pages":"14791641261431771"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147694228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"A novel approach to diabetes-related foot ulcers/disease: First report of bipolar conventional RF lumbar sympathetic block\".","authors":"","doi":"10.1177/14791641261438547","DOIUrl":"10.1177/14791641261438547","url":null,"abstract":"","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 2","pages":"14791641261438547"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147597064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of drug-coated balloons and plain old balloon angioplasty in hemodialysis patients with Below-The-Knee artery disease.","authors":"Zhen-Yi Jin, Chun-Min Li, Lu-Bo Ma, Jia-Hao Wen, Hua-Liang Ren, Sheng-Xing Wang","doi":"10.1177/14791641261418911","DOIUrl":"10.1177/14791641261418911","url":null,"abstract":"<p><p>ObjectiveTo descriptively compare the clinical outcomes of drug-coated balloons (DCB) and plain balloon angioplasty (POBA) in hemodialysis patients with Below-The-Knee (BTK) peripheral artery disease.MethodsThis retrospective study included 96 hemodialysis patients (DCB:55 POBA:41). Outcomes included changes in Rutherford grade, wound healing, freedom from target lesion revascularization (CD-TLR), survival, and amputation-free survival.ResultsBoth groups demonstrated improvement in Rutherford grade at 12 months. Wound healing occurred in 60.6% (95% CI 42.1-76.8) of the DCB group and 50.0% (95% CI 32.0-67.9) of the POBA group. Amputation-free survival was 72.7% (95% CI 59.0-83.0) with DCB and 67.7% (95% CI 52.5-80.0) with POBA. Freedom from CD-TLR was 78.9% (95% CI 65.0-88.5) for DCB and 91.6% (95% CI 79.0-97.0) for POBA. No clear between-group differences were observed.ConclusionNo significant differences were observed between DCB and POBA in this small retrospective cohort.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"23 2","pages":"14791641261418911"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}